NCT07863193
Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 28 → 35 locations
- Minor Trial sites expanded: 23 → 28 locations
- Start date pushed from Oct 1, 2026 to Oct 21, 2026
- Minor Study sites: 23 to 28
- Start date changed from estimate of Oct 2026 to Oct 1, 2026
- Minor Trial sites expanded: 20 → 23 locations
- Minor Trial sites expanded: 4 → 20 locations
- Minor Study title expanded, about 1 word
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Proportion of participants achieving EGSS success, defined as a score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease from their baseline score
Timeframe: Week 12
Absolute change from baseline in inflammatory lesion count (ILC)
Timeframe: Week 12
Absolute change from baseline in non-inflammatory lesion count (ILC)
Timeframe: Week 12
Arms and interventions
DenifanstatExperimental
PlaceboPlacebo comparator
Drugs: Denifanstat
Other: Placebo
Sites
35 sites in 1 country